Qingfang W. Miao

NHC Key Laboratory Of Biotechnology For Microbial Drugs, Chinese Academy Of Medical Sciences & Peking Union Medical College
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Combined therapy with ALK inhibitors and a novel EGFR-targeting antibody‒drug conjugate as a strategy for ALK-rearranged non-small cell lung cancers.

Combined therapy with ALK inhibitors and a novel EGFR-targeting antibody‒drug conjugate as a strategy for ALK-rearranged non-small cell lung cancers.

Journal: Oncogenesis

Published: September 08, 2025

Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer

Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer

Journal: Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

Published: August 04, 2025

Correction to: Preclinical evaluation of 64Cu/177Lu‑labelled anti‑CD30 monoclonal antibody for theranostics in CD30‑positive lymphoma.

Correction to: Preclinical evaluation of 64Cu/177Lu‑labelled anti‑CD30 monoclonal antibody for theranostics in CD30‑positive lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: January 17, 2025

Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.

Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: July 21, 2024

A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.

A new TROP2-targeting antibody-drug conjugate shows potent antitumor efficacy in breast and lung cancers.

Journal: NPJ precision oncology

Published: August 30, 2023

Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2.

Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2.

Journal: International journal of biological macromolecules

Published: February 07, 2023

Novel 5-Fluorouracil Carbonate-Loaded Liposome: Preparation, In Vitro, and In Vivo Evaluation as an Antitumor Agent.

Novel 5-Fluorouracil Carbonate-Loaded Liposome: Preparation, In Vitro, and In Vivo Evaluation as an Antitumor Agent.

Journal: Molecular pharmaceutics

Published: June 22, 2022

Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models.

Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models.

Journal: European journal of nuclear medicine and molecular imaging

Published: June 13, 2022

Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer.

Rational Design and Systemic Appraisal of an EGFR-Targeting Antibody-Drug Conjugate LR-DM1 for Pancreatic Cancer.

Journal: Journal of medicinal chemistry

Published: May 06, 2022

Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle.

Promoted antitumor therapy on pancreatic cancer by a novel recombinant human albumin-bound miriplatin nanoparticle.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: June 22, 2021

Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.

Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.

Journal: Military Medical Research

Published: April 26, 2021

Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.

Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.

Journal: European journal of medicinal chemistry

Published: January 05, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026